Articles related to DEPRESSION

A single 25-mg dose of synthetic psilocybin with structured psychological support produced rapid, large-magnitude reductions in suicidal ideation through 12 weeks in 20 treatment-resistant adults with major depressive disorder, with two participants experiencing worsening ideation.

Antidepressant prescription trajectories remained stable or absent for the majority of Swedish adults who continued working past age 65, with no worsening pattern observed around work exit in a 10-year longitudinal cohort of 32,849 participants.

Adjunctive low-dose naltrexone did not separate from placebo on depressive symptom reduction in a 38-patient randomized trial of adults with moderate major depressive disorder on existing antidepressants.

Adjunctive cognitive behavioral therapy reduced depressive symptoms and ideation scores versus treatment as usual in a 93-patient feasibility trial of esketamine for major depression with suicidal ideation.

A JAMA Psychiatry network meta-analysis ranked lumateperone highest for efficacy and aripiprazole highest for acceptability among five FDA-approved adjunctive atypical antipsychotics for major depressive disorder.

FDA priority review vouchers granted to three psychedelic developers and a recent executive order may accelerate regulatory timelines for psilocybin and related compounds, with clinical availability potentially within 12 months pending positive Phase 3 data.